Brief Treatment for Posttraumatic Stress Disorder
The primary goal of this study is to examine whether a brief treatment approach for PTSD is equally efficacious in the treatment of active duty service members relative to a first line treatment approach that requires much greater treatment dose.
- Eligible Ages
- Over 18 Years
- Eligible Genders
- Accepts Healthy Volunteers
- Male and female active duty military personnel who have deployed in support of a post-9/11 conflict seeking treatment for PTSD
- Diagnosis of PTSD
- Ability to speak, read and write English
- Not currently engaged in psychosocial treatment for PTSD
- Individuals taking psychotropic medications agree to work with their prescriber to remain on stable doses of any prescribed psychotropic medications for the duration of the intervention and through the first follow-up assessment as much as possible and as medically indicated.
- Current suicide or homicide risk meriting crisis intervention
- Active psychosis
- Moderate to severe brain damage
- Study Type
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Single (Outcomes Assessor)
Written exposure therapy
|5 sessions of imaginal exposure therapy.||
CPT, cognitive only
|12 sessions of cognitive therapy.||
- NCT ID
- Boston VA Research Institute, Inc.
Study ContactAlan Peterson, Ph.D.
The goal of this randomized clinical trial is to investigate if a brief, written intervention for posttraumatic stress disorder (PTSD), Written Exposure Therapy (WET), is equally efficacious as an evidenced-based behavioral therapy, Cognitive Processing Therapy-Cognition only (CPT-C), in the treatment of PTSD in active duty military men and women with a diagnosis of PTSD who have deployed in support of a post-9/11. The primary study outcome will be change in symptom severity as assessed by the Clinician Administered PTSD Scale for Diagnostic and Statistical Manual-5 edition (CAPS-5). Independent assessors will evaluate participants using the CAPS-5 at baseline, 10- (post-treatment), 20-, and 30-week intervals after the start of treatment.